AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02242266 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo via the grey HandiHaler®
Description: oral inhalation via the grey HandiHaler®
Study NCT02242266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo via the grey HandiHaler®
Description: oral inhalation via the grey HandiHaler®
Study NCT00499499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7107
Description: E7107 will be administered as an intravenous infusion over 30 minutes at a starting dose of 0.6 mg/m\^2 to the first cohort of patients. The same dose will be given on Days 1 and 8 of a 21-day cycle. Dose escalation will not occur until the maximum tolerated dose is reached. The selection of subsequent dose levels will be performed according to an accelerated design.
Study NCT02124525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N-acetylcysteine
Description: N-acetylcysteine 3000mg a day for 12 weeks versus Placebo for 12 weeks
Study NCT00921739 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Esophageal sparing IMRT
Description: 6 fractions/week of 2Gy each for 29 fx (58 Gy), 31 fx (62 Gy), 33 fx (66 Gy), 35 fx (70 Gy), or 37 fx (74 Gy).
Study NCT03525041 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG
Description: CABG will be performed using standard surgical techniques. All procedures will be performed with cardiopulmonary bypass(CPB). Saphenous vein(SV)will be used as conduit but harvesting methods will not be prescribed, and utilization of the left internal mammary artery (LIMA) is recommended when a left anterior descending (LAD) graft is indicated. The technical details of bypass grafting will not be prescribed. Complete revascularization will be performed, judging by the surgical investigator.
Study NCT02972671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiStent (MT005) Coronary Artery Stent
Description: Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
Study NCT02972671 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience Coronary Artery Stent
Description: Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
Study NCT00417508 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sip feeding
Description: Daily supplement with sip feeding, 2 packages(each package containing 200 ml,20 g protein and 300 kcal)
Study NCT00417508 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Advice
Description: The patients will receive ordinary dietary advice with a recommendation of four meals per day or similar dietary advice and no daily sip feeding supplements.
Study NCT00489138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem
Description: 1g a day by drip of 30 min
Study NCT03137537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: lower heart rate in heart failure patients.
Study NCT03137537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Procedure prescribed to compare the active effect of a medicine.
Study NCT03525041 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mitral valve annuloplasty
Description: Surgical techniques for mitral valve annuloplasty may need to be adjusted at the discretion of the surgeon, as based on intra-operative findings that may not be previously recognized in the pre-operative evaluation.
Study NCT03011710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProVari v2.5 (E-cigarette)
Description: An electronic cigarette or e-cigarette is a handheld electronic device that vaporizes a flavored liquid. The user inhales the vapor. The fluid in the e-cigarette, called e-liquid, is usually made of nicotine, propylene glycol, glycerine, and flavorings.
Study NCT03011710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Marlboro Gold (Conventional cigarette)
Description: Conventional cigarette
Study NCT03011710 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cigarette tip
Description: Placebo device
Study NCT02352129 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CMR using T1 mapping technique
Description: the level of myocardial fibrosis for patient suffering of cardiomyopathy dilated will be quantified using CMR T1 mapping technique
Study NCT02352129 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CMR using T1 mapping technique
Description: the level of myocardial fibrosis for patient suffering of cardiomyopathy dilated will be quantified using CMR T1 mapping technique
Study NCT02269306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphen citrate
Description: The study was carried out on 150 patients with PCOS. Initial clomiphen citrate (CC) doses were 50 mg daily for 5 days starting on cycle day 3. In the case of an absent response, doses were increased to 100 and 150 mg daily in subsequent cycles. First ovulation with CC was used as the end point.
Study NCT02530684 — intervention group
Intervention type: OTHER
Intervention: insole
Description: Insoles available on the market without prescription
Study NCT01848730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNV2197944
Study NCT01848730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02564796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa and Iron
Description: Patients in the treatment group will receive weekly EPO injections and iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization) They will be followed for 14 weeks.
Study NCT02564796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iron
Description: Patients in the treatment group will not receive any extra intervention outside of standard of care. They will receive iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization). They will be followed for 14 weeks.
Study NCT01545804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: All enrolled patients will receive Lenalidomide, 25 mg orally daily, until objective disease progression, development of unacceptable toxicity, or voluntary discontinuation by the subjects.
Study NCT04089618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBLM
Description: Complex 8 week Mind-Body program.
Study NCT00946751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam Tablets, 750 mg (Sandoz Inc.)
Study NCT04395404 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: Patients with unilateral ASS, with and without the prosthesis in situ, are analysed by 3D- magnetic resonance imaging (MRI) with 64 channel head coil using T1 and T2 weighted, DIXON/ IDEAL, and T2 inversion recovery sequences.
Study NCT02768363 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: aglatimagene besadenovec
Description: Aglatimagene besadenovec will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second aglatimagene besadenovec injection will be 2-3 weeks after the first followed by 14 days of valacyclovir.
Study NCT02768363 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second placebo injection will be 2-3 weeks after the first followed by 14 days of valacyclovir.
Study NCT02768363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valacyclovir
Description: Oral prodrug to be given for 14 days starting the day after each aglatimagene besadenovec or placebo injection.
Study NCT02768363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: valacyclovir
Description: Oral prodrug to be given for 14 days starting the day after each aglatimagene besadenovec or placebo injection.
Study NCT00981370 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: deferasirox
Description: Treatment starting dose of 20mg/kg/day based on subjects baseline LIC (liver iron concentration) and gradually escalate the dose to a maximum of 35 mg/kg/day based upon toxicity. Duration is up to a max of 12 months.
Study NCT03846804 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Karius Test
Description: Next-generation sequencing of blood and synovial fluid samples for pathogen identification in children with musculoskeletal infections
Study NCT00371280 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: orbital implant
Description: Implantation of pegged versus unpegged hydroxyapatite orbital implants
Study NCT01721993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T121
Study NCT01721993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Study NCT02211079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911
Description: JNJ-54861911, 50 mg (2\*25 mg tablets) orally once daily from Day 2 to Day 9.
Study NCT02211079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Single oral dose of caffeine 100 mg (2\*50 mg tablets), on Day 1, 2, and 9.
Study NCT02211079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Single oral dose of midazolam 2 mg (1 mL, 2 mg/mL solution), on Day 1, 2, and 9.
Study NCT02211079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolbutamide
Description: Single oral dose of Tolbutamide 500 mg tablet, on Day 1, 2, and 9.
Study NCT00001880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Cyclosporin beginning day -4 and intravenous Methotrexate on days +1, +3, and +6 will be given
Study NCT00001880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin
Description: Cyclosporin beginning day -4 and intravenous Methotrexate on days +1, +3, and +6 will be given
Study NCT01441180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS7977
Description: drug intervention
Study NCT01441180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS7977
Description: drug intervention
Study NCT00946751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keppra (Levetiracetam) Tablets, 750 mg (UCB Pharma, Inc)
Study NCT01596725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H5N1)
Description: Dose A without Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
Study NCT01596725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H5N1)
Description: Dose B without Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
Study NCT01596725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H5N1); Adjuvant
Description: Dose B with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
Study NCT01596725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H5N1); Adjuvant
Description: Dose C with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
Study NCT01596725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H5N1); Adjuvant
Description: Dose D with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
Study NCT01596725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline Placebo
Description: Placebo; intramuscular, deltoid, Day 0 and Day 21
Study NCT03985917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Singing Group Intervention Program
Description: Each session will start with (1) relaxation, vocal warm-up and breething exercises; (2) vocal technique training; (3) memorization and interpretation of music and lyrics; (4) session breaks of 20 minutes for socialization; (5) preparation of a final choir show; (6) vocal tuning tests.
Study NCT03985917 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alternative Social and Leisure Activities
Description: Day care centers provide social and leisure activities opportunities for older adults. The control group is free to enroll in these activities.
Study NCT01565928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDV3100
Description: 4 x 40 mg capsules, orally, once per day
Study NCT00339469 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: LIFE
Description: We are evaluating the effects of a legume enriched, low glycemic index, high fermentable fiber diet, on CRP, and C-peptide participants with four possible combinations of the risk factors insulin resistance and history of adenomatous polyps. In a randomized crossover design controlled feeding study each participant consumed the above experimental diet and a control diet for four weeks with a two week washout period between diets. 65 male participants were recruited and randomized into four groups. A secondary objective is to assess whether these endpoints change by IR status or a history of adenomas. In addition, potential fecal markers of CRC risk are being measured to assess changes in gastrointestinal inflammation, including mRNA from exfoliated fecal colonocytes. To our knowledge this is the first controlled feeding study: 1. to examine the effects of legumes or a low GI diet on markers of inflammation
Study NCT01771887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education program
Description: education program in 6 hours and monitoring phone every 15 days
Study NCT03682328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vertebroplasty
Description: Cement augmentation of the vertebral body
Study NCT03682328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: kyphoplaty
Description: Cement augmentation of the vertebral body
Study NCT04554823 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Education
Description: Will attend lectures on health education about Health and Physical Education, healthy eating, overcoming barriers, Back to routine, Physical Activity Options and Dealing with Stress and Depression
Study NCT04554823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Will attend lectures on health education about Health and Physical Education, healthy eating, overcoming barriers, Back to routine, Physical Activity Options and Dealing with Stress and Depression
Study NCT04554823 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Physical Exercise
Description: Supervised physical training program of combined exercises for 24 weeks, with frequency of 3 times weekly and duration of 60 minutes, an unsupervised flexibility training program 2 times a week.
Study NCT04554823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: Supervised physical training program of combined exercises for 24 weeks, with frequency of 3 times weekly and duration of 60 minutes, an unsupervised flexibility training program 2 times a week.
Study NCT02684565 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BCAA High Protein supplement
Description: Subjects will be randomly assigned to take high BCAA or low-BCAA protein a day for 4 weeks, then switch to BCAA or low-BCAA protein for 4 weeks after a 2-week washout.
Study NCT02684565 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BCAA Low Protein supplement
Description: Subjects will be randomly assigned to take high BCAA or low-BCAA protein a day for 4 weeks, then switch to BCAA or low-BCAA protein for 4 weeks after a 2-week washout.
Study NCT01441180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: drug intervention
Study NCT04943380 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cxbladder
Description: The Cxbladder Detect test, developed by Pacific Edge Ltd (O'Sullivan 2012; Holyoake 2008; National Health Committee 2015b) is a molecular diagnostic test, which consists of five mRNA transcripts measured in a small volume of urine.
Study NCT00130637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclizumab
Study NCT03526081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chamomile Tea
Description: Chamomile Tea in 300mL hot water
Study NCT03526081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parsley based drink
Description: 3.2 g dried parsley in 300mL hot water
Study NCT03526081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parsley Yogurt
Description: 3.2 g dried parsley in 100g plain yogurt
Study NCT03526081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apigenin
Description: Apigenin capsule mixed with 300mL hot water
Study NCT03526081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parsley-based drink (II)
Description: 3.2 g dried parsley in 300mL hot water
Study NCT00994149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide
Description: 10mg/kg/d divide every 8 hours
Study NCT00994149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ora-plus
Description: placebo, give every 8 hours.
Study NCT04227990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plinabulin
Description: Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
Study NCT04227990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Pegfilgrastim is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
Study NCT04227990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: Pegfilgrastim is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
Study NCT01441180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RBV
Description: drug intervention
Study NCT01686061 — intervention group
Intervention type: OTHER
Intervention: No intervention- only one time survey
Study NCT00772616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: closed-loop administration using bispectral index as the single input for the controller.
Study NCT00772616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: dosage according to usual criteria
Study NCT01049100 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymphadenectomy
Description: paraaortal and pelvic lymphadenectomy laparoscopic or open
Study NCT01049100 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Standard Staging
Description: clinical Staging (FIGO) (examination in narcosis, biopsy, cystoscopy, rectoscopy) X-Ray Radiograph of Thorax, Ultrasound of abdomen, CT abdomen / pelvis positive, suspicious lymphnodes--> CT controlled biopsy
Study NCT02789995 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Human biological samples
Description: Blood sample - Muscle biopsy - Bone marrow sample (mesenchymal stem cells)
Study NCT00142298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine (LdT)
Description: Telbivudine was to be supplied as white to off-white, oval, bi-convex tablets for the 200 mg tablets and white to off-white ovaloid, slightly curved, beveled edges, film coated tablets for the 600 mg tablets. Study drug (600 mg) was to be self-administered by patients orally (p.o.) in a once daily regimen for 104 weeks; for study consistency, the daily dose had to be taken at the same time each day, with or without food.
Study NCT02420340 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HOPES Program (Helping Older People Experience Success)
Description: Weekly group skills training classes aimed at improving skills and knowledge in areas related to successful living in the community including: independent living, healthy living, social skills, leisure skills, and management of health care.
Study NCT00797771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adi Insulin pump
Description: insulin delivery will be defined by the physician
Study NCT00242216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir-boosted atazanavir
Description: 100 mg ritonavir plus 300 mg atazanavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.
Study NCT00242216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir-boosted fosamprenavir
Description: 100 mg ritonavir plus 1,400 mg fosamprenavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.
Study NCT03145974 — intervention group
Intervention type: DEVICE
Intervention: mechanical ventilation
Description: ventilatory support
Study NCT01675791 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALK tree AIT 0.5 DU